uniQure N.V. QURE 深 沪
等待开盘 01-28 09:30:00 美东时间
24.37
-0.900
-3.56%
华盛通- 最 高25.65
- 今 开25.00
- 成交量 126.29万股
- 最 低 24.29
- 昨 收 25.27
- 总市值 14.78亿
- 52周最高 71.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.76
- 委 比 88.33%
- 总股本 6065.64万
- 历史最高 82.49
- 量 比 0.58
- 振 幅 5.38%
- 历史最低 3.73
- 每 手 1
- 风险率 14.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多uniQure Announces Type A Meeting Scheduled with FDA
uniQure N.V. has scheduled a Type A meeting with the U.S. FDA to discuss the BLA data package for AMT-130, its gene therapy for Huntington’s disease, aiming for accelerated approval. CEO Matt Kapusta expressed commitment to timely access for patients and collaboration with the FDA. The公司 plans to provide a regulatory update post-meeting and is advancing a pipeline of gene therapies for severe diseases.
01-09 12:05
Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points o...
2025-12-17 23:07
What's Going On With uniQure Stock On Tuesday?
uniQure shares slid nearly 31% in a month as the FDA raised concerns over whether AMT-130 Phase 1/2 data can support approval.
2025-12-17 01:17
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
2025-12-16 20:05
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of B Riley Financial Inc (NASDAQ:RILY) rose sharply in pre-market tradin...
2025-12-16 18:53
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
美股周涨跌榜 | Capricor周涨402.6%，核心药物取得关键性临床试验进展；DBRG周涨45.4%，曝软银有意收购
Capricor周涨402.6%，核心药物取得关键性临床试验进展；DBRG周涨45.4%，曝软银有意收购；UiPath本周上涨34.7%，财报表现强劲>>
2025-12-06 10:17
uniQure shares are trading lower after the company that in the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission.
uniQure shares are trading lower after the company that in the FDA conveyed tha...
2025-12-04 21:54
